Vanguard Fiduciary Trust
ACRS icon

Vanguard Fiduciary Trust’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Buy
907,173
+278,314
+44% +$1.24M ﹤0.01% 2202
2026
Q1 		$2.36M Buy
+628,859
New +$2.12M ﹤0.01% 2477

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Fiduciary Trust's ACRS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Aclaris Therapeutics (ACRS) stake by 44% in Q2 2026, buying an estimated $1.24M and bringing the position to 907,173 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2202.

Vanguard Fiduciary Trust first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Vanguard Fiduciary Trust held 907,173 shares of Aclaris Therapeutics worth $4.8M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 278,314 Aclaris Therapeutics shares in Q2 2026, an estimated $1.24M.
  • Aclaris Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2202 holding.
  • Vanguard Fiduciary Trust first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.